Laura Axelrod Potter, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fetal Death | 1 | 2023 | 430 | 0.770 |
Why?
|
| Abortion, Induced | 1 | 2023 | 457 | 0.580 |
Why?
|
| Fragile X Syndrome | 3 | 2020 | 116 | 0.460 |
Why?
|
| Dilatation | 2 | 2023 | 303 | 0.240 |
Why?
|
| Philadelphia Chromosome | 1 | 2022 | 117 | 0.200 |
Why?
|
| Antiemetics | 1 | 2022 | 186 | 0.180 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2023 | 733 | 0.180 |
Why?
|
| Language Therapy | 1 | 2020 | 25 | 0.180 |
Why?
|
| Lovastatin | 1 | 2020 | 116 | 0.170 |
Why?
|
| GABA Agonists | 1 | 2019 | 105 | 0.160 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2023 | 1064 | 0.110 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 1524 | 0.110 |
Why?
|
| Gene Silencing | 1 | 2019 | 1512 | 0.100 |
Why?
|
| Metformin | 1 | 2019 | 912 | 0.100 |
Why?
|
| Hemorrhage | 1 | 2023 | 3606 | 0.090 |
Why?
|
| Education, Medical | 1 | 2023 | 1727 | 0.090 |
Why?
|
| Mothers | 1 | 2020 | 2181 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 2803 | 0.070 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 3150 | 0.070 |
Why?
|
| Pregnancy | 2 | 2023 | 29658 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 5247 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 11653 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 11908 | 0.050 |
Why?
|
| Pyridazines | 1 | 2022 | 200 | 0.040 |
Why?
|
| Doxycycline | 1 | 2022 | 336 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2023 | 41247 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2022 | 327 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2022 | 225 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2023 | 80121 | 0.040 |
Why?
|
| Telecommunications | 1 | 2020 | 80 | 0.040 |
Why?
|
| Vincristine | 1 | 2022 | 1036 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2022 | 629 | 0.040 |
Why?
|
| Vomiting | 1 | 2022 | 647 | 0.040 |
Why?
|
| Fragile X Mental Retardation Protein | 1 | 2019 | 117 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 13238 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2022 | 2218 | 0.030 |
Why?
|
| Imidazoles | 1 | 2022 | 1175 | 0.030 |
Why?
|
| California | 1 | 2020 | 1404 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2022 | 2203 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2022 | 1927 | 0.030 |
Why?
|
| Intubation, Intratracheal | 1 | 2022 | 1328 | 0.030 |
Why?
|
| Learning | 1 | 2023 | 1729 | 0.030 |
Why?
|
| Humans | 8 | 2023 | 759255 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2022 | 1989 | 0.020 |
Why?
|
| Language | 1 | 2020 | 1525 | 0.020 |
Why?
|
| Pyridines | 1 | 2022 | 2875 | 0.020 |
Why?
|
| Female | 3 | 2023 | 390240 | 0.020 |
Why?
|
| Curriculum | 1 | 2023 | 3711 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2023 | 4776 | 0.020 |
Why?
|
| Child | 3 | 2020 | 79623 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2020 | 12386 | 0.020 |
Why?
|
| Communication | 1 | 2020 | 3846 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 5635 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 3754 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2019 | 4371 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 18110 | 0.010 |
Why?
|
| Prognosis | 1 | 2019 | 29561 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2019 | 41935 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2019 | 23362 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2019 | 64879 | 0.010 |
Why?
|
| Adolescent | 1 | 2020 | 87560 | 0.010 |
Why?
|
| Male | 2 | 2020 | 358719 | 0.010 |
Why?
|
| Middle Aged | 1 | 2022 | 219653 | 0.000 |
Why?
|
| Adult | 1 | 2022 | 219390 | 0.000 |
Why?
|
| Animals | 1 | 2019 | 167838 | 0.000 |
Why?
|